Company Profile

Kytopen Corporation
Profile last edited on: 2/8/22      CAGE: 7WNK9      UEI: NGLCLMGPFSV6

Business Identifier: Cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

501 Massachusetts Avenue
Cambridge, MA 02139
   (443) 799-3072
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Kytopen Corp, spun out of MIT, is developing platforms designed to accelerate the discovery and manufacturing of gene-modified cell therapies. Pioneering a novel and non-viral process to engineer human cells for therapeutic applications in immuno-oncology and genetic disorders, the company's primary product -- Flowfect -- combines microfluidics and automation to make the discovery process of gene-modified cell therapies easier, faster, and more cost-effective than the state-of-the art solutions. The technology is integrated with automated liquid handling systems will reduce the cost and accelerate time to market for discovering and manufacturing next-generation cell and gene therapies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Paulo A Garcia -- CEO & Co-Founder

  Ross Beighley -- Senior Systems Engineer

  Cullen R Buie -- Co-Founder

  Greg Crescenzi -- Chief Commercial Officer

  Michael Elliott -- Chief Operating Officer

  Bethany Grant -- VP of Engineering and Product Development

  Rameech Mccormack -- R&D Engineer 2

  Norman Wen -- Director of Engineering